As linkers become increasingly sophisticated, more emphasis is being placed on the methods of bioconjugation between linker and antibody, with the goal of producing homogeneous adc populations. The basic principle behind adcs is to link antibodies with cytotoxic drugs through a linker, allowing the drug to be selectively delivered to tumor cells, thus enhancing therapeutic efficacy and reducing toxicity to healthy cells Target, antibody, linker, payload, and conjugation method.
'Naked' woman ripped for wearing body paint to gym issues apology
Linker tethering payload to antibody is vital for adc
This review provides an overview of linkers of 17 approved adcs and recent innovations in linker design, focusing on drug release triggers, bioconjugation strategies, the impact of spacers on hydrophilicity, traceless drug release, and linker architecture, as well as a discussion of the bystander effect, offering insights for the rational.
An adc consists of a monoclonal antibody and a potent cytotoxic payload connected through a chemical linker. An ideal linker should be stable in the circulatory system and release the cytotoxic payload specifically in the tumor
